Vedolizumab register in patients with inflammatory bowel disease in Germany

Vedolizumab register in patients with inflammatory bowel disease in Germany - VEDOibd

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00008174

Enrollment

300

Registered

2015-04-27

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K50

Interventions

Group 1: Effectiveness of therapy and serious adverse events with a Vedolizumab therapy in patients with inflammatory bowel disease. Data on drug history , disease history and the well-being of the pa

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: IBD ( inflammatory bowel disease) and Vedolizumab therapy

Exclusion criteria

Exclusion criteria: age >18 years

Design outcomes

Primary

Measure	Time frame
Effectiveness of therapy and serious adverse events with a Vedolizumab therapy in patients with inflammatory bowel disease.	—

Secondary

Measure	Time frame
not defined	—

Countries

Germany

Contacts

Public ContactBernd Bokemeyer

Kompetenznetz Darmerkrankungen

sekretariat@kompetenznetz-darmerkrankungen.de0431-58090640

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 27, 2026